A phase III, double-blind, placebo-controlled, monotherapy study of imeglimin (TIMES 1)

Trial Profile

A phase III, double-blind, placebo-controlled, monotherapy study of imeglimin (TIMES 1)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms TIMES 1
  • Sponsors Cmic; Poxel; Sumitomo Dainippon Pharma
  • Most Recent Events

    • 10 Jul 2018 According to a Poxel media release, efficacy data readout from this trial is expected in the second quarter of 2019.
    • 03 Jul 2018 Status changed from recruiting to active, no longer recruiting, according to a Poxel media release.
    • 25 Jun 2018 According to Poxel media release, data from this trial are expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top